For research use only. Not for therapeutic Use.
<p style=/line-height:25px/>SRT1720 hydrochloride is a selective activator of human SIRT1 (EC1.5 = 0.16 μM) versus the closest sirtuin homologues, SIRT2 and SIRT3 (SIRT2: EC1.5 = 37 μM;SIRT3: EC1.5 > 300 μM).<br>IC50 Value: 0.16 μM(EC1.5 for SIRT1)<br>Target: SIRT1<br>SRT 1720 binds to the SIRT1 enzyme-peptide substrate complex at an allosteric site amino-terminal to the catalytic domain and lower the Michaelis constant for acetylated substrates. In diet-induced obese and genetically obese mice, SRT1720 improved insulin sensitivity, lower plasma glucose, and increase mitochondrial capacity. Thus, SRT1720 is a promising new therapeutic agent for treating diseases of ageing such as type 2 diabetes.</p>
Catalog Number | I000075 |
CAS Number | 1001645-58-4 |
Synonyms | N-[2-[3-(piperazin-1-ylmethyl)imidazo[2,1-b][1,3]thiazol-6-yl]phenyl]quinoxaline-2-carboxamide;hydrochloride |
Molecular Formula | C25H23N7OS • XHCl |
Purity | ≥95% |
Target | Sirtuin |
Solubility | DMSO: 38 mg/mL, H2O: <1 mg/mL |
Storage | 3 years -20C powder |
IC50 | 0.16 μM(EC1.5 for SIRT1) |
InChIKey | DTGRRMPPXCRRIM-UHFFFAOYSA-N |
Reference | <p style=/line-height:25px/> |